D.A. Davidson & CO. Has $1.96 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

D.A. Davidson & CO. grew its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 88,919 shares of the company’s stock after purchasing an additional 2,408 shares during the period. D.A. Davidson & CO.’s holdings in Teva Pharmaceutical Industries were worth $1,960,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in TEVA. FMR LLC grew its position in Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after buying an additional 20,762,226 shares in the last quarter. Janus Henderson Group PLC grew its position in Teva Pharmaceutical Industries by 7,945.2% during the third quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock worth $86,350,000 after buying an additional 4,732,374 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Teva Pharmaceutical Industries by 237.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock worth $60,863,000 after buying an additional 2,376,668 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its position in Teva Pharmaceutical Industries by 6.8% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after buying an additional 2,204,623 shares in the last quarter. Finally, State Street Corp grew its position in Teva Pharmaceutical Industries by 10.0% during the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after buying an additional 1,778,268 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on TEVA. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. UBS Group reduced their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.57.

Teva Pharmaceutical Industries Stock Down 1.5 %

NYSE TEVA opened at $16.75 on Friday. The business has a fifty day moving average price of $19.92 and a two-hundred day moving average price of $18.49. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The stock has a market capitalization of $18.97 billion, a PE ratio of -11.55, a PEG ratio of 1.44 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.